Treatment of the common nodal peripheral T-cell lymphomas (PTCLs), which include PTCL, not otherwise specified (PTCL, NOS), anaplastic large cell lymphomas, and T-follicular helper lymphomas, is evolving. These entities are currently treated similarly with CHOP or CHOEP for CD30-negative diseases or brentuximab vedotin plus CHP for CD30-positive diseases, followed by consolidation with autologous stem cell transplant in first remission. Ongoing improvements in PTCL classification, identification of predictive biomarkers, and development of new targeted agents will lead to more specific therapies that address the unique biologic and clinical properties of each entity. For example, widespread efforts focused on molecular profiling of PTCL, NOS is likely to identify distinct subtypes that warrant different treatment approaches. New agents, such as EZH1/2 and JAK/STAT pathway inhibitors, are broadening treatment options for relapsed or refractory disease. Furthermore, promising strategies optimizing immune therapy for PTCL are currently under investigation and have potential to significantly alter the therapeutic landscape. Ongoing front-line study designs incorporate understanding of disease biology and drug sensitivities and are poised to evaluate whether newer targeted agents should be incorporated into the front-line settings for the various disease entities. Although current treatment strategies lump most disease entities together, future treatment will include distinct strategies for each disease subtype that optimizes therapy for individuals. This movement towards individualized therapy will ultimately lead to dramatic improvements in prognosis for patients with PTCL.
Skip Nav Destination
Review Article|
February 2, 2024
Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs)
Alison J Moskowitz,
Alison J Moskowitz
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Search for other works by this author on:
Robert N Stuver,
Robert N Stuver
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Search for other works by this author on:
Steven M Horwitz
Memorial Sloan Kettering Cancer Center, New York, New York, United States
* Corresponding Author; email: horwitzs@mskcc.org
Search for other works by this author on:
Blood blood.2023021789.
Article history
Submitted:
December 5, 2023
Revision Received:
January 26, 2024
Accepted:
January 26, 2024
Citation
Alison J Moskowitz, Robert N Stuver, Steven M Horwitz; Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs). Blood 2024; blood.2023021789. doi: https://doi.org/10.1182/blood.2023021789
Download citation file:
My Account
Sign InAdvertisement intended for health care professionals
1
Crossref
Cited By
Advertisement intended for health care professionals
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal